UBS Group’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-2,802
| Closed | -$56.8K | – | 11355 |
|
|
2022
Q4 | $56.8K | Buy |
2,802
+1,356
| +94% | +$20.8K | ﹤0.01% | 6648 |
|
|
2022
Q3 | $16K | Buy |
1,446
+266
| +23% | +$3.02K | ﹤0.01% | 7754 |
|
|
2022
Q2 | $14K | Buy |
1,180
+158
| +15% | +$2.55K | ﹤0.01% | 7457 |
|
|
2022
Q1 | $22K | Buy |
1,022
+717
| +235% | +$19K | ﹤0.01% | 7372 |
|
|
2021
Q4 | $10K | Sell |
305
-133
| -30% | -$3.71K | ﹤0.01% | 8842 |
|
|
2021
Q3 | $11K | Sell |
438
-757
| -63% | -$13.5K | ﹤0.01% | 7933 |
|
|
2021
Q2 | $16K | Buy |
+1,195
| New | +$14.8K | ﹤0.01% | 7605 |
|
|
2021
Q1 | – | Sell |
-1,943
| Closed | -$16K | – | 9690 |
|
|
2020
Q4 | $16K | Buy |
1,943
+221
| +13% | +$1.74K | ﹤0.01% | 7135 |
|
|
2020
Q3 | $13K | Buy |
+1,722
| New | +$15.3K | ﹤0.01% | 6663 |
|
|
2020
Q1 | – | Sell |
-964
| Closed | -$14K | – | 8581 |
|
|
2019
Q4 | $14K | Buy |
+964
| New | +$14.1K | ﹤0.01% | 7114 |
|
|
2019
Q2 | – | Sell |
-2,235
| Closed | -$30K | – | 8276 |
|
|
2019
Q1 | $30K | Buy |
2,235
+689
| +45% | +$10K | ﹤0.01% | 5953 |
|
|
2018
Q4 | $22K | Sell |
1,546
-2,069
| -57% | -$33.7K | ﹤0.01% | 6721 |
|
|
2018
Q3 | $65K | Buy |
3,615
+1,631
| +82% | +$28.3K | ﹤0.01% | 5960 |
|
|
2018
Q2 | $28K | Sell |
1,984
-1,916
| -49% | -$33.7K | ﹤0.01% | 6455 |
|
|
2018
Q1 | $75K | Buy |
3,900
+2,604
| +201% | +$56.3K | ﹤0.01% | 5422 |
|
|
2017
Q4 | $29K | Buy |
1,296
+1,078
| +494% | +$34.5K | ﹤0.01% | 6270 |
|
|
2017
Q3 | $8K | Buy |
+218
| New | +$8.13K | ﹤0.01% | 7019 |
|
UBS Group's OPNT Position: Q1 2023 in Review
UBS Group sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 2,802 shares — an estimated $56.8K sold.
UBS Group first reported a position in OPNT in Q3 2017 and held it in 17 quarters. The position peaked at $75K in Q1 2018. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.
- UBS Group reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- UBS Group sold 2,802 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $56.8K.
- UBS Group first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 17 quarters.
- UBS Group's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $75K in Q1 2018.
- 0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.
Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.